Assessment of cognitive safety in clinical drug development

Jonathan P. Roiser, Pradeep J. Nathan, Adrian P. Mander, Gabriel Adusei, Kenton H. Zavitz, Andrew D. Blackwell

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodological principles for measuring cognition during clinical drug development, including study design and statistical analysis, from Phase I through to postmarketing. The crucial issue of how cognition should be assessed is emphasized, especially the sensitivity of measurement. We also consider how best to interpret the magnitude of any identified effects, including comparison with benchmarks. We conclude by discussing strategies for the effective communication of cognitive risks.

Original languageEnglish
Pages (from-to)445-453
Number of pages9
JournalDrug Discovery Today
Volume21
Issue number3
DOIs
Publication statusPublished - 1 Mar 2016

Cite this

Roiser, J. P., Nathan, P. J., Mander, A. P., Adusei, G., Zavitz, K. H., & Blackwell, A. D. (2016). Assessment of cognitive safety in clinical drug development. Drug Discovery Today, 21(3), 445-453. https://doi.org/10.1016/j.drudis.2015.11.003
Roiser, Jonathan P. ; Nathan, Pradeep J. ; Mander, Adrian P. ; Adusei, Gabriel ; Zavitz, Kenton H. ; Blackwell, Andrew D. / Assessment of cognitive safety in clinical drug development. In: Drug Discovery Today. 2016 ; Vol. 21, No. 3. pp. 445-453.
@article{c2082ab669534254877d6abfca4512f9,
title = "Assessment of cognitive safety in clinical drug development",
abstract = "Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodological principles for measuring cognition during clinical drug development, including study design and statistical analysis, from Phase I through to postmarketing. The crucial issue of how cognition should be assessed is emphasized, especially the sensitivity of measurement. We also consider how best to interpret the magnitude of any identified effects, including comparison with benchmarks. We conclude by discussing strategies for the effective communication of cognitive risks.",
author = "Roiser, {Jonathan P.} and Nathan, {Pradeep J.} and Mander, {Adrian P.} and Gabriel Adusei and Zavitz, {Kenton H.} and Blackwell, {Andrew D.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.drudis.2015.11.003",
language = "English",
volume = "21",
pages = "445--453",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "3",

}

Roiser, JP, Nathan, PJ, Mander, AP, Adusei, G, Zavitz, KH & Blackwell, AD 2016, 'Assessment of cognitive safety in clinical drug development', Drug Discovery Today, vol. 21, no. 3, pp. 445-453. https://doi.org/10.1016/j.drudis.2015.11.003

Assessment of cognitive safety in clinical drug development. / Roiser, Jonathan P.; Nathan, Pradeep J.; Mander, Adrian P.; Adusei, Gabriel; Zavitz, Kenton H.; Blackwell, Andrew D.

In: Drug Discovery Today, Vol. 21, No. 3, 01.03.2016, p. 445-453.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Assessment of cognitive safety in clinical drug development

AU - Roiser, Jonathan P.

AU - Nathan, Pradeep J.

AU - Mander, Adrian P.

AU - Adusei, Gabriel

AU - Zavitz, Kenton H.

AU - Blackwell, Andrew D.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodological principles for measuring cognition during clinical drug development, including study design and statistical analysis, from Phase I through to postmarketing. The crucial issue of how cognition should be assessed is emphasized, especially the sensitivity of measurement. We also consider how best to interpret the magnitude of any identified effects, including comparison with benchmarks. We conclude by discussing strategies for the effective communication of cognitive risks.

AB - Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodological principles for measuring cognition during clinical drug development, including study design and statistical analysis, from Phase I through to postmarketing. The crucial issue of how cognition should be assessed is emphasized, especially the sensitivity of measurement. We also consider how best to interpret the magnitude of any identified effects, including comparison with benchmarks. We conclude by discussing strategies for the effective communication of cognitive risks.

UR - http://www.scopus.com/inward/record.url?scp=84950239610&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2015.11.003

DO - 10.1016/j.drudis.2015.11.003

M3 - Review Article

VL - 21

SP - 445

EP - 453

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3

ER -